Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 7/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 5/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624323 | 0.96 | TAS1R3 (0.46) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4367734 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4367894 | 0.93 | CTSK (0.43) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL13634972 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4370748 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4370734 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL13624425 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4367724 | 0.93 | CTSL (0.41) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4367886 | 0.93 | CTSK (0.43) | TAS1R3TAS1R1MEN1KMT2ACTSL | |
| SCHEMBL4367302 | 0.93 | TAS1R3 (0.45) | TAS1R3TAS1R1MEN1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | TAS1R3 3970/4885TAS1R1 3363/4885MEN1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.